GlassScriptPhysician profile
John R Duke
NPI 1356301147
$4,618.52
in general payments reported to CMS, 2019-2025
35 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $769 · 2021: $551 · 2022: $576 · 2023: $717 · 2024: $498 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.11 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $554.01 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $508.16 | 2021-2024 | Vraylar |
| Amgen INC. | $482.30 | 2019-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $394.93 | 2019-2025 | Breztri |
| Dexcom, INC. | $354.47 | 2019-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $264.95 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.85 | 2022-2025 | |
| Glaxosmithkline, LLC. | $230.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $153.90 | 2019-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.20 | 2019-2024 | Jardiance |
| Sunovion Pharmaceuticals INC. | $142.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.59 | 2020-2023 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $132.68 | 2021-2025 | Gvoke Hypopen |
| Allergan, INC. | $90.54 | 2019-2020 | |
| Medtronic, INC. | $87.90 | 2024-2025 | Minimed 780g |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $85.52 | 2020-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $70.16 | 2020-2023 | Gattex |
| Insulet Corporation | $64.13 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $57.86 | 2019 | |
| Exact Sciences Corporation | $49.27 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $48.05 | 2020-2022 | |
| Shire North American Group INC | $46.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.85 | 2019 | |
| Astellas Pharma US INC | $30.07 | 2022-2023 | Myrbetriq |
| Aimmune Therapeutics, INC. | $25.13 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $20.53 | 2025 | Gemtesa |
| Advanced Respiratory, INC | $20.21 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.67 | 2020 | |
| Viatris Specialty LLC | $16.49 | 2025 | Yupelri |
| Currax Pharmaceuticals LLC | $16.39 | 2024 | Onzetra Xsail, Contrave |
| Biocryst US Sales Co., LLC | $16.30 | 2023 | Orladeyo |
| Medtronic Minimed, INC. | $15.70 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.05 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.48 | 2020 | |
| Strongbridge US INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.